Extended Efficacy of Once-Daily Atomoxetine in ADHD

J Gordon Millichap

doi:10.15844/pedneurbriefs-18-7-1

Extended Efficacy of Once-Daily Atomoxetine in ADHD

Pediatric Neurology Briefs

Volume 18 (2004): Issue 7

By: J Gordon Millichap

Open Access

|Jul 2004

Abstract

The efficacy of atomoxetine administered once daily (final dose 1.3 +/- 0.3 mg/kg; mean 44.5 mg per day; range 10-80 mg per day) in the morning was assessed throughout the day, including evening and early morning, in a total of 197 children, 6 to 12 years of age (71% male), diagnosed with attention-deficit/hyperactivity disorder (ADHD) (69% had combined subtype ADHD, and 35% had comorbid oppositional defiant disorder).

References

Kelsey DK Sumner CR Casat CD Coury DL Quintana H Saylor KE Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial Pediatrics 2004 Jul 114 1 e1 8 10.1542/peds.114.1.e1 15231966
Open DOI Search in Google Scholar Back to article
Akhondzadeh S Mohammadi MR Khademi M Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371] BMC Psychiatry 2004 Apr 8 4 9 10.1186/1471-244X-4-9 15070418
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-18-7-1 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 49 - 50

Published on: Jul 1, 2004

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Attention-Deficit/Hyperactivity Disorder,

Double-Blind,

Placebo-Controlled Trial

© 2004 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 18 (2004): Issue 7